September 18, 2026
Bonus Content: Moderna Rose 137% in a Month on One Melanoma Result
Editor’s Note: See the following from our friend Josh Baylin. Josh is one of the greatest tech investors in America. For years, he helped manage $200 million at SAC Capital (the elite fund run by Steve Cohen, who owns the NY Mets). He purchased two $60,000 Nvidia supercomputers to run his own quant fund. And he even broke tech stories at Bloomberg for many years. But what he’s sharing next could be the biggest call of his career…
What Sam Altman’s launching next could be 500 times bigger than ChatGPT, unlock an industry worth over $1 million per American, and send one small group of stocks soaring as this news spreads.
Click here to learn about the stocks tied to Sam Altman’s Next Venture.
At test sites across America, even the cleaning staff could go to prison if they told you what they’ve seen.
That’s because, at these sites, Sam Altman’s next venture is officially live.
It’s a new use for AI that may sound “disturbing” to some.
But like it or not… it’s already working 10,000 times faster than many of the smartest human scientists in the world.
It’s backed by Jeff Bezos, Peter Thiel, and Elon Musk (who calls the underlying tech “the most disruptive force in history”).
And it threatens to destabilize one of the world’s largest (and most-disliked) industries… saving millions of innocent people in the process.
To learn about this before the average investor is reading all about it in the news…
Click here to learn what’s happening – and to see the critical stocks to own as this takes off.
Regards,
Josh Baylin
Analyst, Stansberry Research
P.S. What I’m sharing with you today is the same investing blueprint that would have turned $1,000 into $3 million… and even $5.8 million in the past. Click here to see how getting in early on Sam Altman’s next big move could be the best decision you make all year.
Moderna Rose 137% in a Month on One Melanoma Result
Markets do not need a reason to keep moving. They only need a story that hasn’t been fully disproven. For Moderna, that story is intismeran autogene, and it has now carried the stock roughly 137% higher over a single month without a single new filing, analyst upgrade, or trial result to justify Thursday’s additional 6% leg to roughly $154.
No Moderna announcement, filing, analyst action, or trial result landed Thursday morning to explain the move. The single event doing all the work is the Phase 3 INTerpath-001 topline readout reported August 19, in which the combination of intismeran autogene plus pembrolizumab met its primary endpoint of recurrence-free survival and the key secondary endpoint of distant metastasis-free survival, demonstrating statistically significant and clinically meaningful improvements compared with pembrolizumab alone. That result, confirmed weeks ago, is still pricing the stock today.
What the Data Actually Says
INTerpath-001 represents the first positive Phase 3 readout for an individualized neoantigen therapy and an mRNA-based cancer therapy, as well as the first Phase 3 study to demonstrate a clinically meaningful improvement over pembrolizumab alone in the adjuvant melanoma setting. The underlying Phase 2b data, presented at ASCO in June, quantifies the magnitude: five-year follow-up showed a sustained benefit with intismeran in combination with Keytruda, reducing the risk of recurrence or death by 49% compared to Keytruda alone.
Merck is Moderna’s partner on that individualized neoantigen program, which now spans nine Phase 2 and Phase 3 trials across melanoma, non-small cell lung cancer, bladder, and renal cell carcinoma. The Phase 3 adjuvant melanoma trial is fully enrolled. Moderna and Merck have said they plan to present further data from follow-up analyses of the Phase 3 program at an upcoming medical meeting. The specific Phase 3 details beyond the topline endpoints that already moved markets remain outstanding.
Expectations vs. Reality: The Analyst Divide
This is where the beat-vs.-guide tension sharpens. Rothschild & Co Redburn downgraded Moderna to Sell from Neutral with a price target of $81, viewing the Phase 3 INTerpath-001 trial as scientifically sound but commercially overpriced. Rothschild says the subsequent share price reaction implies a near-ubiquitous usage across tumor types for which there is little or no data, which the firm struggles to reconcile. Argus, by contrast, upgraded Moderna to Buy from Hold with a $180 price target following FDA approval for updated 2026-2027 COVID-19 vaccines. The average 12-month price target sits at $119.56, with a high of $170 and a low of $45, a range that itself narrates the disagreement.
Meanwhile, Moderna moved to capitalize on its elevated share price. The company priced $2.6 billion aggregate principal amount of 0.00% Convertible Senior Notes due 2032, upsized from an originally announced $2.0 billion offering. The initial conversion price is approximately $210.58, a 47.5% premium to the $142.77 share price on the pricing date.
The Next Binary: Madrid, October 23-27
The ESMO Congress 2026 is scheduled from October 23-27 in Madrid, Spain at IFEMA Madrid, and stands as one of the most influential annual gatherings in oncology worldwide. Further Phase 3 INTerpath-001 data is the next swing factor, with Madrid’s October oncology congress as the nearest widely watched public data window. Whether Moderna presents at ESMO or reserves full data for a later regulatory submission is not yet confirmed, but the market is treating the congress as a live event risk either way.
Options Market Analysis
The options chain reflects that uncertainty precisely. Moderna’s 30-day option implied volatility is at 79, compared to its 52-week range of 57 to 138. That places current IV well above the floor but meaningfully below the August spike, which briefly touched the top of that range when INTerpath-001 first crossed the wire. The call-to-put ratio on September 17 was 3 calls to 1 put, with focus concentrated on October calls. The directional skew is clear. Whether it is also overcrowded is the more important question.
At IV of 79 against a 52-week low of 57, premium is elevated but not historically extreme. For traders who expect the stock to remain range-bound into Madrid, an iron condor or short strangle in the October expiration collects that elevated volatility without requiring a directional call. For those expecting further upside, a defined-risk bull call spread, long the $155 strike, short the $175 strike, October expiration, caps the outlay while participating in a continuation move.
Structured Trade Framework
Bull case: If you believe ESMO produces additional intismeran data reinforcing INTerpath-001, a defined-risk structure would be a debit call spread in October, targeting the $170-$177 range near the 52-week high. Risk is limited to the premium paid.
Bear case: For traders expecting mean-reversion toward the analyst consensus near $120, a defined-risk put spread in the November expiration provides time for the thesis to develop without suffering Madrid-day volatility on a naked short.
Neutral case: An October iron condor, short the $135 put and $175 call, long the $120 put and $190 call, monetizes IV at 79 while defining maximum loss on both wings.
Risk Analysis and Forward Outlook
The primary risks are binary and asymmetric. A positive ESMO presentation could extend the run toward the 52-week high of $176.66. Silence, no Moderna abstract selected, could trigger a sharp IV collapse and price reversal toward the $119 consensus. The convertible note structure introduces dilution risk at $210.58, a level the stock has not tested, but the capped calls limit that overhang to a defined ceiling.
BioNTech edged up only 1% on Thursday despite operating its own mRNA oncology program, confirming that markets are pricing Moderna’s specific asset, not a sector-wide re-rating. Novavax saw modest sympathy. Neither changes the calculus for MRNA holders.
Action Checklist
- ESMO congress dates: October 23-27, Madrid. Monitor abstract releases in early October for Moderna/Merck intismeran presentations.
- IV watch: 30-day IV at 79. A move above 100 approaching ESMO would signal premium-selling opportunity; a collapse below 65 would reduce cost of long-premium structures.
- Defined-risk bias: At $154 with a $119 consensus target, any long structure should cap maximum loss at a known premium rather than holding unhedged equity through a binary.
- Phase 3 data window: INTerpath-001 topline is already public; further Phase 3 details remain pending. ESMO is a preview risk, not the final event.
- Earnings date: November 5, 2026 (estimated). A second IV event within six weeks of ESMO creates layered volatility risk for positions held through both dates.
